Insider Buying: PureTech Health (LON:PRTC) Insider Buys £939.44 in Stock

PureTech Health plc (LON:PRTC) insider Sharon Barber-Lui bought 93,944 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average price of GBX 1 per share, with a total value of £939.44.

Sharon Barber-Lui also recently made the following trade(s):

• On Tuesday, July 7th, Sharon Barber-Lui purchased 29,868 shares of PureTech Health stock. The shares were purchased at an average cost of GBX 119 per share, with a total value of £35,542.92.

PureTech Health Price Performance

LON:PRTC traded down GBX 0.48 during trading hours on Friday, hitting GBX 119.12. The company’s stock had a trading volume of 512,639 shares, compared to its average volume of 1,072,302. The business’s 50-day moving average is GBX 127.71 and its two-hundred day moving average is GBX 126.71. PureTech Health plc has a 52-week low of GBX 104.71 and a 52-week high of GBX 146.40. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. The company has a market capitalization of £289.96 million, a PE ratio of -2.59 and a beta of 0.79.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a research report on Monday, July 13th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, PureTech Health presently has an average rating of “Buy” and a consensus target price of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.